Abstract

The present study sets out to analyze the effective dose of remimazolam tosilate combined with nalbuphine in inhibiting somatic motor reflexes during induced abortion. From September 2022 to June 2023, individuals with induced abortion were selected. After intravenous injection of nalbuphine for 3 min and administration of remimazolam, the procedure was performed. Vital signs such as mean arterial pressure and heart rate were observed at different time points, before anesthesia induction (T0), after nalbuphine injection (T1), after remimazolam injection (T2), at the end of surgery (T3) and at the time of recovery from anesthesia (T4). The dosage of remimazolam, operation duration, recovery time and adverse reactions like uterine contraction pain, dizziness, hypoxemia, bradycardia, nausea and vomiting were recorded. Mean effective dose and 95 % effective dose of remimazolam+nalbuphine in induced abortion were tested using the Efron’s biased coin design method. Dose of 0.015 mg/kg nalbuphine, depicted effective dose and 95 % effective dose remimazolam in inhibiting the somatic motor reflexes during induced abortion which was found to be 0.439 mg/kg (95 % CI: 0.375-0.543 ) and 0.570 mg/kg (95 % CI: 0.500-1.533), respectively. Mean remimazolam dosage in patients was (22.21±5.02) mg with operation duration of (5.70±1.78) min and recovery time of (3.67±1.15) min. The major adverse reactions were hypoxemia, uterine contraction pain and dizziness. The above results indicated that the effective dose and 95 % effective dose of remimazolam in inhibiting the patients’ somatic motor reflexes were 0.439 mg/kg (95 % CI: 0.375-0.543 mg/kg) and 0.570 mg/kg (95 % CI: 0.500-1.533 mg/kg), respectively and the combination of them was safe in induced abortion.